By targeting these receptors directly, Tanaka and colleagues hoped to shut down lupus pathology at the earliest point in the process, preventing interferon release and the subsequent autoimmune ...

The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva®) for the treatment of ...

Following his medical training in Pathology and Rheumatology at the National University of Singapore and the Singapore General Hospital in Singapore, Dr. Mohan undertook his doctoral thesis work ...

By analyzing genes encoding B-cell and T-cell receptors, the model could screen for conditions like HIV, type 1 diabetes, and ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® ...